Bio Capital Stock vs Accounts Payable Analysis
| BPTH Stock | USD 0.77 0.03 3.75% |
Bio Path financial indicator trend analysis is way more than just evaluating Bio Path Holdings prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Path Holdings is a good investment. Please check the relationship between Bio Path Capital Stock and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Capital Stock vs Accounts Payable
Capital Stock vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Path Holdings Capital Stock account and Accounts Payable. At this time, the significance of the direction appears to have very week relationship.
The correlation between Bio Path's Capital Stock and Accounts Payable is 0.25. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Bio Path Holdings, assuming nothing else is changed. The correlation between historical values of Bio Path's Capital Stock and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of Bio Path Holdings are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Capital Stock i.e., Bio Path's Capital Stock and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.25 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Accounts Payable
An accounting item on the balance sheet that represents Bio Path obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Bio Path Holdings are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Bio Path's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Path Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. The Bio Path's current Sales General And Administrative To Revenue is estimated to increase to 179.88, while Selling General Administrative is projected to decrease to under 2.4 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 3K | 33K | 52K | 32.5K | Interest Income | 3K | 33K | 52K | 31.0K |
Bio Path fundamental ratios Correlations
Click cells to compare fundamentals
Bio Path Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Path fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 22.7M | 16.5M | 26.6M | 16.0M | 3.2M | 3.1M | |
| Other Current Liab | 673K | 881K | 688K | 801K | 1.2M | 1.3M | |
| Total Current Liabilities | 1.2M | 1.2M | 958K | 1.7M | 1.9M | 2.0M | |
| Total Stockholder Equity | 21.1M | 15.1M | 25.5M | 14.2M | 441K | 419.0K | |
| Property Plant And Equipment Net | 670K | 519K | 428K | 356K | 178K | 344.7K | |
| Net Debt | (20.0M) | (13.4M) | (23.5M) | (10.2M) | (939K) | (986.0K) | |
| Retained Earnings | (56.3M) | (67.2M) | (77.7M) | (91.5M) | (107.6M) | (102.2M) | |
| Accounts Payable | 486K | 100K | 106K | 667K | 457K | 479.9K | |
| Cash | 20.4M | 13.8M | 23.8M | 10.4M | 1.1M | 999.4K | |
| Non Current Assets Total | 670K | 519K | 428K | 356K | 178K | 169.1K | |
| Non Currrent Assets Other | (13.4M) | 288K | 225K | 158K | 76K | 79.8K | |
| Cash And Short Term Investments | 20.4M | 13.8M | 23.8M | 10.4M | 1.1M | 999.4K | |
| Common Stock Shares Outstanding | 132.9K | 192.4K | 336.3K | 363.8K | 478K | 292.6K | |
| Liabilities And Stockholders Equity | 22.7M | 16.5M | 26.6M | 16.0M | 3.2M | 3.1M | |
| Non Current Liabilities Total | 330K | 236K | 153K | 113K | 873K | 916.7K | |
| Other Current Assets | 788K | 2.2M | 2.4M | 5.2M | 2.0M | 2.1M | |
| Other Stockholder Equity | 77.4M | 82.3M | 103.1M | 105.7M | 108.0M | 113.4M | |
| Total Liab | 1.6M | 1.4M | 1.1M | 1.8M | 2.8M | 2.9M | |
| Property Plant And Equipment Gross | 670K | 519K | 1.3M | 1.3M | 1.2M | 1.3M | |
| Total Current Assets | 22.0M | 16.0M | 26.1M | 15.6M | 3.0M | 2.9M | |
| Common Stock | 1K | 4K | 5K | 7K | 8K | 950.0 | |
| Common Stock Total Equity | 11K | 1K | 4K | 5K | 4.5K | 4.3K | |
| Net Tangible Assets | 1.2M | 21.1M | 15.1M | 25.5M | 29.3M | 30.7M | |
| Retained Earnings Total Equity | (39.2M) | (47.7M) | (56.3M) | (67.2M) | (60.5M) | (57.5M) | |
| Capital Surpluse | 47.2M | 49.0M | 77.4M | 82.3M | 94.6M | 99.4M | |
| Property Plant Equipment | 406K | 303K | 231K | 428K | 492.2K | 282.1K | |
| Accumulated Depreciation | (330K) | (592K) | (726K) | (798K) | (718.2K) | (682.3K) | |
| Net Invested Capital | 21.1M | 15.1M | 25.5M | 14.2M | 441K | 419.0K | |
| Net Working Capital | 20.7M | 14.8M | 25.2M | 13.9M | 1.1M | 1.1M |
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.